FINNENCE ▪ THE WIRE FILE
THE WIRE · № 83910
News▼ Bearish
Extrawell Pharmaceutical Abandons Negotiations For Possible Sale Of Convertible Bonds
KINDNews
DIRECTION▼ Bearish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Abandoned convertible bond sale signals financing difficulty for the issuer.
Financing setback for small pharma
CATALYST TO WATCH
Alternative financing announcement
MAIN RISK
Small-cap, limited market impact
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)2026-10-16 11:12 UTC
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)2026-10-16 11:12 UTC
→CORRELATIONshares Healthcare
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development2026-10-16 11:30 UTC
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development2026-10-16 11:30 UTC
←CORRELATIONshares Healthcare
A stock sale is expected to bring City Therapeutics about $200 million.2026-10-16 02:37 UTC
A stock sale is expected to bring City Therapeutics about $200 million.2026-10-16 02:37 UTC
←CORRELATIONshares Healthcare
City Therapeutics prices IPO at $18 per share, raising $200M2026-10-16 02:53 UTC
City Therapeutics prices IPO at $18 per share, raising $200M2026-10-16 02:53 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.